A major goal for hepatitis C virus (HCV) vaccine development is to elicit broadly neutralizing antibodies (bNAbs) against the E1E2 glycoprotein complex located on the viral surface. Inducing HCV bNAbs requires engagement of their germline B cell precursors. HCV glycoproteins usually do not bind and activate inferred ge...
Fabian Mulder, F. Cannac, Joan Capella-Pujol et al.· bioRxiv· 0 citations
These findings provide proof-of-concept that epitope-focused nanoparticle immunogens can target partially occluded, immunoquiescent bnAb epitopes, laying the groundwork for pan-betacoronavirus vaccines that provide broad protection and strengthen pandemic preparedness.
Panpan Zhou, Ziqi Feng, Wan-ting He et al.· bioRxiv· 0 citations
Hepatitis C virus (HCV) affects 47 million people and causes 239,000 deaths annually, yet no vaccine is on the horizon. Generating a stable native-like mimic of the envelope complex E1E2, the only target for known neutralizing antibodies, is an important aim for HCV vaccine development. Starting from a recombinant E1E2...
Joan Capella-Pujol, Fabian Mulder, F. Cannac et al.· Nature Communications· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.